Published in Arterioscler Thromb Vasc Biol on September 23, 2004
Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proc Natl Acad Sci U S A (2012) 3.50
Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ (2008) 2.98
Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis. Arterioscler Thromb Vasc Biol (2016) 1.39
HBV pathogenesis in animal models: recent advances on the role of platelets. J Hepatol (2007) 1.20
Pharmacogenetics of aspirin resistance: a comprehensive systematic review. Br J Clin Pharmacol (2008) 1.18
Antiplatelet drug therapy moderates immune-mediated liver disease and inhibits viral clearance in mice infected with a replication-deficient adenovirus. Clin Vaccine Immunol (2007) 1.04
Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes. Circ Cardiovasc Genet (2013) 0.99
Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy. Br J Clin Pharmacol (2011) 0.99
Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes. Br J Clin Pharmacol (2010) 0.98
Antiplatelet drug 'resistance'. Part 1: mechanisms and clinical measurements. Nat Rev Cardiol (2009) 0.97
Genetic determinants of platelet response to clopidogrel. J Thromb Thrombolysis (2011) 0.96
Microfluidic assay of platelet deposition on collagen by perfusion of whole blood from healthy individuals taking aspirin. Clin Chem (2013) 0.95
Clinical importance of aspirin and clopidogrel resistance. World J Cardiol (2010) 0.95
Molecular defects of the platelet P2 receptors. Purinergic Signal (2011) 0.85
Polymorphisms of MDR1, CYP2C19 and P2Y12 genes in Indian population: effects on clopidogrel response. Indian Heart J (2013) 0.83
A novel ultrasound-based method to evaluate hemostatic function of whole blood. Clin Chim Acta (2009) 0.83
Chronic hepatitis B: role of anti-platelet therapy in inflammation control. Cell Mol Immunol (2015) 0.83
Treatment and prevention of gastrointestinal bleeding in patients receiving antiplatelet therapy. World J Crit Care Med (2015) 0.82
The effect of acetylsalicylic acid resistance on prognosis of patients who have developed acute coronary syndrome during acetylsalicylic acid therapy. Can J Cardiol (2007) 0.81
Increased platelet expression of glycoprotein IIIa following aspirin treatment in aspirin-resistant but not aspirin-sensitive subjects. Br J Clin Pharmacol (2014) 0.81
The combination of EPA+DHA and low-dose aspirin ingestion reduces platelet function acutely whereas each alone may not in healthy humans. Prostaglandins Leukot Essent Fatty Acids (2012) 0.81
The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19. Expert Opin Drug Metab Toxicol (2015) 0.79
Effector CD8 T cell trafficking within the liver. Mol Immunol (2012) 0.79
Aspirin has limited ability to modulate shear-mediated platelet activation associated with elevated shear stress of ventricular assist devices. Thromb Res (2016) 0.79
Effect of antiplatelet therapy on patients undergoing gastroenterological surgery: thromboembolic risks versus bleeding risks during its perioperative withdrawal. World J Surg (2015) 0.79
Bleeding tendency in dual antiplatelet therapy with aspirin/clopidogrel: rescue of the template bleeding time in a single-center prospective study. Thromb J (2012) 0.79
Platelet glycoprotein IIIa gene polymorphism (Leu33Pro) and aspirin resistance in a very elderly Chinese population. Genet Test Mol Biomarkers (2014) 0.78
Decreased Threshold of Aggregation to Low-Dose Epinephrine is Evidence of Platelet Hyperaggregability in Patients with Thrombosis. Hematol Rep (2014) 0.78
Case files of the Medical Toxicology Fellowship at Banner Good Samaritan Medical Center in Phoenix, AZ: a non-warfarin anticoagulant overdose. J Med Toxicol (2009) 0.77
Aspirin resistance and promoting blood circulation and removing blood stasis: current situation and prospectives. Evid Based Complement Alternat Med (2014) 0.77
Boosting platelet inhibition in poor responder to aspirin and clopidogrel undergoing percutaneous coronary intervention: role of tirofiban. J Blood Med (2010) 0.77
Chinese herbal medicine for aspirin resistance: a systematic review of randomized controlled trials. Evid Based Complement Alternat Med (2014) 0.77
Hepatic effector CD8(+) T-cell dynamics. Cell Mol Immunol (2014) 0.77
P2RY1 and P2RY12 polymorphisms and on-aspirin platelet reactivity in patients with coronary artery disease. Int J Lab Hematol (2012) 0.77
Prevention of chronic HBV infection induced hepatocellular carcinoma development by using antiplatelet drugs. Hepatobiliary Surg Nutr (2012) 0.76
Combined aspirin and clopidogrel resistance associated with recurrent coronary stent thrombosis. Clin Res Cardiol (2006) 0.76
Better detection of platelet aggregation in patients with metabolic syndrome using epinephrine and ADP. Diabetol Metab Syndr (2014) 0.75
Balancing potency of platelet inhibition with bleeding risk in the early treatment of acute coronary syndrome. West J Emerg Med (2009) 0.75
Remote Assessment of Platelet Function in Patients with Acute Stroke or Transient Ischaemic Attack. Stroke Res Treat (2017) 0.75
The application of thromboelastogram in detection of indexes of antiplatelet therapy for coronary heart disease. J Thorac Dis (2016) 0.75
Critical Overview on the Benefits and Harms of Aspirin. Pharmaceuticals (Basel) (2010) 0.75
A review of antiplatelet drugs, coronary artery diseases and cardiopulmonary bypass. J Extra Corpor Technol (2010) 0.75
Current developments in anti-platelet therapy. Wien Med Wochenschr (2006) 0.75
Mitigation of device-associated thrombosis and thromboembolism using combinations of heparin and tirofiban. J Extra Corpor Technol (2006) 0.75
Aspirin prophylaxis for the prevention of thrombosis: expectations and limitations. Thrombosis (2012) 0.75
Sulfasalazine and its metabolites inhibit platelet function in patients with inflammatory arthritis. Clin Rheumatol (2014) 0.75
Aspirin resistance - does it clinically matter? Clin Res Cardiol (2006) 0.75